Abstract:Rationale: The prognosis of gastric cancer (GC) patients is poor, and there is limited therapeutic efficacy due to genetic heterogeneity and difficulty in early-stage screening. Here, we developed and validated an individualized gene set-based prognostic signature for gastric cancer (GPSGC) and further explored survival-related regulatory mechanisms as well as therapeutic targets in GC.Methods: By implementing machine learning, a prognostic model was established based on gastric cancer gene expression datasets from 1699 patients from five independent cohorts with reported full clinical annotations. Analysis of the tumor microenvironment, including stromal and immune subcomponents, cell types, panimmune gene sets, and immunomodulatory genes, was carried out in 834 GC patients from three independent cohorts to explore regulatory survival mechanisms and therapeutic targets related to the GPSGC. To prove the stability and reliability of the GPSGC model and therapeutic targets, multiplex fluorescent immunohistochemistry was conducted with tissue microarrays representing 186 GC patients. Based on multivariate Cox analysis, a nomogram that integrated the GPSGC and other clinical risk factors was constructed with two training cohorts and was verified by two validation cohorts.Results: Through machine learning, we obtained an optimal risk assessment model, the GPSGC, which showed higher accuracy in predicting survival than individual prognostic factors. The impact of the GPSGC score on poor survival of GC patients was probably correlated with the remodeling of stromal components in the tumor microenvironment. Specifically, TGFβ and angiogenesis-related gene sets were significantly associated with the GPSGC risk score and poor outcome. Immunomodulatory gene analysis combined with experimental verification further revealed that TGFβ1 and VEGFB may be developed as potential therapeutic targets of GC patients with poor prognosis according to the GPSGC. Furthermore, we developed a nomogram based on the GPSGC and other clinical variables to predict the 3-year and 5-year overall survival for GC patients, which showed improved prognostic accuracy than clinical characteristics only.Conclusion: As a tumor microenvironment-relevant gene set-based prognostic signature, the GPSGC model provides an effective approach to evaluate GC patient survival outcomes and may prolong overall survival by enabling the selection of individualized targeted therapy.

Development of a Streamlined NGS-based TCGA Classification Scheme for Gastric Cancer and Its Implications for Personalized Therapy

Identification of Tumor Mutation Burden, Microsatellite Instability, and Somatic Copy Number Alteration Derived Nine Gene Signatures to Predict Clinical Outcomes in STAD.

Identifying gastric cancer molecular subtypes by integrating DNA-based hierarchical classification strategy and clinical stratification

A transcriptomic study for identifying cardia- and non-cardia-specific gastric cancer prognostic factors using genetic algorithm-based methods

Immunogenomic Classification of Gastric Cancer Based on the Tumor Microenvironments Expression of PD-L1 and CD8+T-cell Infiltration.

Hierarchical learning of gastric cancer molecular subtypes by integrating multi‐modal DNA‐level omics data and clinical stratification

Bioinformatics-based analysis of programmed cell death pathway and key prognostic genes in gastric cancer: Implications for the development of therapeutics

Implementing an On-Slide Molecular Classification of Gastric Cancer: A Tissue Microarray Study

Classification of Gastric Cancers Based on Immunogenomic Profiling.

Molecular classification reveals the diverse genetic features and prognosis of gastric cancer: a multi-omics consensus ensemble clustering

Molecular classification reveals the diverse genetic and prognostic features of gastric cancer: A multi-omics consensus ensemble clustering

Implementing an integrated molecular classification for gastric cancer from endoscopic biopsies using on-slide tests

A novel genomic classification system of gastric cancer via integrating multidimensional genomic characteristics

Identification of Immunogenic Cell-Death-Related Subtypes and Development of a Prognostic Signature in Gastric Cancer

Identification of angiogenesis-related subtypes and risk models for predicting the prognosis of gastric cancer patients

Characterization of Immune-Related Molecular Subtypes and a Prognostic Signature Correlating with the Response to Immunotherapy in Patients with Gastric Cancer

Integrated Assessment of PD-L1 Expression and Molecular Classification Facilitates Therapy Selection and Prognosis Prediction in Gastric Cancer

Molecular Subtypes and CD4+ Memory T Cell-Based Signature Associated With Clinical Outcomes in Gastric Cancer

Protein Expression-Based Classification Of Gastric Cancer By Immunohistochemistry Of Tissue Microarray

Emerging Molecular Classifications and Therapeutic Implications for Gastric Cancer

Identification of a Tumor Microenvironment-relevant Gene set-based Prognostic Signature and Related Therapy Targets in Gastric Cancer